Regeneron Pharmaceuticals, Inc.
REGN
$589.48
-$8.68-1.45%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.43% | -2.68% | 12.04% | 11.85% | 11.45% |
| Total Other Revenue | 75.98% | -29.94% | -15.58% | -17.43% | 50.79% |
| Total Revenue | 3.62% | -3.70% | 10.33% | 10.65% | 12.32% |
| Cost of Revenue | 16.17% | 6.51% | 16.72% | 16.60% | 12.75% |
| Gross Profit | -7.67% | -15.44% | 4.11% | 5.79% | 11.93% |
| SG&A Expenses | -16.42% | -8.13% | 7.39% | 11.54% | 16.38% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.03% | 2.26% | 13.91% | 15.12% | 13.89% |
| Operating Income | -1.68% | -21.94% | 1.66% | 2.70% | 9.01% |
| Income Before Tax | -6.72% | 29.16% | -16.51% | 34.41% | 50.35% |
| Income Tax Expenses | -35.09% | 552.11% | 436.67% | 47.96% | 71.00% |
| Earnings from Continuing Operations | -2.84% | 12.01% | -20.86% | 33.02% | 47.90% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.84% | 12.01% | -20.86% | 33.02% | 47.90% |
| EBIT | -1.68% | -21.94% | 1.66% | 2.70% | 9.01% |
| EBITDA | -0.34% | -17.68% | 2.69% | 3.72% | 9.75% |
| EPS Basic | -0.07% | 13.16% | -21.60% | 30.81% | 46.40% |
| Normalized Basic EPS | 3.24% | -14.54% | 6.24% | 4.40% | 13.23% |
| EPS Diluted | 3.22% | 15.95% | -20.81% | 29.81% | 46.00% |
| Normalized Diluted EPS | 6.66% | -12.45% | 7.24% | 3.61% | 12.91% |
| Average Basic Shares Outstanding | -2.78% | -1.02% | 0.94% | 1.69% | 1.03% |
| Average Diluted Shares Outstanding | -5.89% | -3.39% | 0.00% | 2.47% | 1.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |